Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURPASS-T1D-1

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 905

NCT06914895

ArmPopulationDoseWeeksEstimandWeight change
Tirzepatide Dose 1Obesity + T2Dn/r49n/rn/r
Tirzepatide Dose 2Obesity + T2Dn/r49n/rn/r
Tirzepatide Dose 3Obesity + T2Dn/r49n/rn/r
Tirzepatide Dose 4Obesity + T2Dn/r49n/rn/r
PlaceboObesity + T2Dn/r49n/rn/r